CDH19–CD3 Antibody Constructs for T-Cell–Mediated Melanoma Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic melanoma, including chemotherapy, targeted therapies, and immunotherapy, have limited efficacy, and there is a need for more effective therapeutic options, particularly for advanced stages of the disease.
Innovation Solution
Development of a multispecific antibody construct that binds to human CDH19 on target cells and CD3 on T cells, leveraging specific CDR sequences to enhance immune targeting of melanoma cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (chemotherapy, targeted therapies, immunotherapy) are used for metastatic melanoma, then treatment options are provided, but efficacy is limited and treatment outcomes remain poor
Solution Approach 1:
The antibody construct is segmented into distinct functional domains: a first binding domain that specifically targets CDH19 on melanoma cells and a second binding domain that targets CD3 on T cells. This segmentation allows each domain to independently perform its specific function, improving overall treatment efficacy by simultaneously achieving tumor targeting and immune activation without the limitations of conventional single-target therapies
Solution Approach 2:
The antibody construct combines multiple functions into a single therapeutic molecule: it simultaneously binds to CDH19 on melanoma cells for tumor-specific targeting, binds to CD3 on T cells to activate the immune system, and thereby provides both direct tumor targeting and indirect immune-mediated tumor destruction. This multi-functionality addresses the poor adaptability of conventional treatments to advanced disease by integrating multiple therapeutic mechanisms
2Reliability
If antibody constructs with multiple binding domains are developed, then immune targeting capability is enhanced, but device complexity increases
Solution Approach 1:
The patent merges the CDH19 binding domain and CD3 binding domain into a single antibody construct molecule. This combining approach enhances immune targeting accuracy by ensuring coordinated action between tumor binding and T cell activation functions, while the merging into one molecular entity prevents excessive complexity compared to using separate therapeutic agents
Data Source
AI summary
Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.